Antimicrobial resistance: Concerns of healthcare providers and people with CF

  18 June 2020

Chronic lung infections and their treatment pose risks for the development of antimicrobial resistance (AMR) in people with cystic fibrosis (PWCF). In this study, we evaluated the attitudes of healthcare providers’ (HCP) and PWCF or their parents’ toward AMR within the international CF community.

These results highlight that AMR is relevant to CF HCP and PWCF internationally, indicating that educational tools and research are warranted.

Author(s): Wendy Bullington, Sarah Hempstead, Alan R. Smyth, Pavel Drevinek, Lisa Saiman, Valerie J. Waters, Scott C. Bell, Donald R. Van Devanter, Patrick A. Flume, Stuart Elborn, Marianne S Muhlebach
Healthy Patients  
Back


Display your AMR technology / product:

Global AMR Technologies Database

  • Preventive – Diagnostic – Antimicrobial technologies
  • Academia – Research Institutes – Start ups – SMEs – Multinationals
  • Early research <-> near market
  • Global reach for funding / co-development / licensing
Display your technology and make use of the Continuous AMR Partnering Initiative >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!